Oscar Health, Inc. 8-K

What Happened

• Oscar Health, Inc. and Oscar Management Corporation filed an 8-K reporting an amended and restated employment agreement with Mario Schlosser, effective June 1, 2026. Mr. Schlosser is transitioning from President of Technology and Chief Technology Officer to the role of Co-Founder & Advisor to the CEO and will continue to serve on the company’s Board of Directors.
• The A&R Employment Agreement sets new compensation and benefit terms for the duration of the agreement, which runs from the effective date until terminated under its terms.

Key Details

• Annual base salary: $370,000, effective June 1, 2026.
• Annual bonus: Mr. Schlosser is no longer eligible for the company’s annual bonus program beginning with calendar year 2026.
• Equity and incentives: He will not receive any new long-term incentive or equity-based awards during the agreement’s term, but will continue to vest in previously granted equity awards according to their existing terms.
• Termination benefits: Mr. Schlosser will not be entitled to cash severance payments or company-subsidized healthcare coverage upon any termination of employment.

Why It Matters

• This filing documents a leadership and compensation change that may affect Oscar Health’s technology leadership structure and executive cost profile. Investors should note the reduced ongoing cash and incentive opportunities in the new role (no bonus, no new equity awards, lower base salary relative to prior executive pay practices) while retention of prior equity vesting and continued board membership provide continuity. The company described the role as focused on advancing its AI and digital health agenda, which is a strategic area investors often monitor for growth and innovation.